Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Atkins

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Nature Communications|June 15, 2013
Model-based rational design of an oncolytic virus with improved therapeutic potentialFabrice Le Bœuf, Cory Batenchuk, Markus Vähä-Koskela, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2007
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flowCaroline J Breitbach, Jennifer M Paterson, Chantal G Lemay, et al.
BMJ Open|December 31, 2017
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysisEmma J M Grigor, Dean A Fergusson, Fatima Haggar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 24, 2018
Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute LeukemiaAlissa Visram, Joseph Aziz, Adam Bryant, et al.
The New England Journal of Medicine|April 3, 2026
CRISPR-Cas12a Gene Editing of <i>HBG1</i> and <i>HBG2</i> Promoters to Treat Sickle Cell DiseaseRabi Hanna, Haydar Frangoul, Luis Pineiro, et al.
Transfusion|August 16, 2014
Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantationGrace Christou, Natasha Kekre, William Petrcich, et al.
Transfusion Medicine Reviews|April 25, 2025
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-AnalysisManoj M Lalu, Samuel Igweokpala, Natasha Kekre, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Blood and marrow transplant clinical trials network state of the Science Symposium 2014Frederick R Appelbaum, Claudio Anasetti, Joseph H Antin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 18, 2014
Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trialBenjamin Hibbert, Bradley Hayley, Robert S Beanlands, et al.
Cancer Cell|October 31, 2003
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsDavid F Stojdl, Brian D Lichty, Benjamin R tenOever, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Nature Communications|June 15, 2013
Model-based rational design of an oncolytic virus with improved therapeutic potentialFabrice Le Bœuf, Cory Batenchuk, Markus Vähä-Koskela, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2007
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flowCaroline J Breitbach, Jennifer M Paterson, Chantal G Lemay, et al.
BMJ Open|December 31, 2017
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysisEmma J M Grigor, Dean A Fergusson, Fatima Haggar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 24, 2018
Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute LeukemiaAlissa Visram, Joseph Aziz, Adam Bryant, et al.
The New England Journal of Medicine|April 3, 2026
CRISPR-Cas12a Gene Editing of <i>HBG1</i> and <i>HBG2</i> Promoters to Treat Sickle Cell DiseaseRabi Hanna, Haydar Frangoul, Luis Pineiro, et al.
Transfusion|August 16, 2014
Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantationGrace Christou, Natasha Kekre, William Petrcich, et al.
Transfusion Medicine Reviews|April 25, 2025
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-AnalysisManoj M Lalu, Samuel Igweokpala, Natasha Kekre, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Blood and marrow transplant clinical trials network state of the Science Symposium 2014Frederick R Appelbaum, Claudio Anasetti, Joseph H Antin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 18, 2014
Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trialBenjamin Hibbert, Bradley Hayley, Robert S Beanlands, et al.
Cancer Cell|October 31, 2003
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsDavid F Stojdl, Brian D Lichty, Benjamin R tenOever, et al.
Pageof 8